Beone Medicines (ONC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.05
- EPS estimate
- $1.66
- EPS surprise
- +23.45%
- Revenue surprise
- +4.95%
- Revenue
- $1.7B
- Revenue estimate
- $1.6B
- Reported
- Aug 5, 2026
BeOne Medicines reported Q2 2026 results on August 5, 2026. Earnings per share were $2.05, beating the $1.66 estimate by 23.45%. Revenue was $1.7 billion against a $1.6 billion consensus, the highest in the table. Compared with Q2 2025, EPS more than doubled from $0.91 and revenue rose about 31% from $1.3 billion.
The table shows a turn from losses to profits. BeOne posted a loss in 13 of the 20 quarters, all before 2025, with annual losses per share of $19.48 in 2022, $8.50 in 2023 and $6.14 in 2024. The one profitable quarter in that stretch was Q3 2023, at $2.01. EPS reached breakeven in Q1 2025 and has been positive since, giving annual EPS of $2.60 for 2025. Revenue grew about eightfold, from $206.4 million in Q3 2021 to $1.7 billion. Results against estimates were uneven, with 11 beats and 9 misses, including a 50.29% miss in Q4 2025.
BeOne reported Q3 between November 4 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether quarterly revenue stays at or above the latest $1.7 billion.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $1.66 | $2.05 | +23.45% | $1.7B | SEC |
| Q1 2026 | May 6, 2026 | $1.54 | $1.96 | +27.52% | $1.5B | SEC |
| Q4 2025 | Feb 26, 2026 | $1.21 | $0.60 | −50.29% | $1.5B | SEC |
| Q3 2025 | Nov 6, 2025 | $0.85 | $1.09 | +28.14% | $1.4B | SEC |
| Q2 2025 | Aug 6, 2025 | $0.39 | $0.91 | +134.90% | $1.3B | SEC |
| Q1 2025 | May 7, 2025 | −$0.57 | $0.00 | +100.00% | $1.1B | SEC |
| Q4 2024 | Feb 27, 2025 | −$1.01 | −$1.43 | −41.28% | $1.1B | SEC |
| Q3 2024 | Nov 12, 2024 | −$1.11 | −$1.15 | −3.24% | $1.0B | SEC |
| Q2 2024 | Aug 7, 2024 | −$2.19 | −$1.15 | +47.47% | $929.2M | SEC |
| Q1 2024 | May 8, 2024 | −$3.09 | −$2.41 | +22.11% | $751.7M | SEC |
| Q4 2023 | Feb 26, 2024 | −$3.49 | −$3.53 | −1.18% | $634.4M | SEC |
| Q3 2023 | Nov 9, 2023 | −$3.38 | $2.01 | +159.38% | $781.3M | SEC |
| Q2 2023 | Aug 2, 2023 | −$3.36 | −$3.64 | −8.29% | $595.3M | SEC |
| Q1 2023 | May 4, 2023 | −$3.66 | −$3.34 | +8.83% | $447.8M | SEC |
| Q4 2022 | Feb 27, 2023 | −$4.64 | −$4.29 | +7.45% | $380.1M | SEC |
| Q3 2022 | Nov 9, 2022 | −$3.91 | −$5.39 | −37.88% | $387.6M | SEC |
| Q2 2022 | Aug 4, 2022 | −$4.01 | −$5.56 | −38.72% | $341.6M | SEC |
| Q1 2022 | May 5, 2022 | −$4.12 | −$4.24 | −2.80% | $306.6M | SEC |
| Q4 2021 | Feb 25, 2022 | −$4.97 | −$6.16 | −23.87% | $214.0M | SEC |
| Q3 2021 | Nov 4, 2021 | −$4.70 | −$4.46 | +5.11% | $206.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Beone Medicines (ONC) last report earnings?
Beone Medicines last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did ONC beat earnings estimates?
Yes. Beone Medicines reported EPS of $2.05 for Q2 2026 against a $1.66 estimate — a 23.45% beat.
How much revenue did ONC report last quarter?
Beone Medicines reported $1.7B in revenue for Q2 2026, against a consensus estimate of $1.6B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.